financetom
Business
financetom
/
Business
/
Uranium Royalty Acquires 2% Gross Revenue Royalty in Canada Uranium Project for $726,500
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Uranium Royalty Acquires 2% Gross Revenue Royalty in Canada Uranium Project for $726,500
May 27, 2025 6:21 AM

09:01 AM EDT, 05/27/2025 (MT Newswires) -- Uranium Royalty ( UROY ) said Tuesday it entered a deal to acquire a 2% gross revenue royalty on the Aberdeen uranium project in Nunavut, Canada for 1 million Canadian dollars ($726,500).

The project is operated by Forum Energy Metals, which retains the right to buy back a quarter of the royalty for CA$1 million for a period of six months after a successful pre-feasibility study, the company said.

The deal is expected to close by the end of May, Uranium Royalty ( UROY ) said.

Shares were over 3% higher in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Capstone Reaffirms $100 Million 2026 Run-Rate Target with Acquisition Closing by December 15th
Capstone Reaffirms $100 Million 2026 Run-Rate Target with Acquisition Closing by December 15th
Nov 10, 2025
Acquisition of $15M stone distributor on track to close before December 15; the multi-location business will add revenue, EBITDA, and scale in a fast-growing category. NEW YORK CITY, NEW YORK / ACCESS Newswire ( ACCS ) / November 10, 2025 / Capstone Holding Corp. ( CAPS ) , a national building products distribution platform, today announced that it expects to...
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Nov 10, 2025
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trialLYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer...
CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE
CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE
Nov 10, 2025
Strategic combination positions combined company to capture AI infrastructure demand at scale Movano shareholders gain exposure to rapidly emerging AI infrastructure pure play platform with differentiated product offering, a growing sales pipeline with attractive credit quality, leadership experienced in large-scale distributed computing and software development, and disciplined capital allocation Merger exchange ratio based upon a Movano per share value...
Veradace Partners Issues Letter to Tiptree Shareholders Regarding the Proposed Sale of Fortegra to DB Insurance
Veradace Partners Issues Letter to Tiptree Shareholders Regarding the Proposed Sale of Fortegra to DB Insurance
Nov 10, 2025
Transaction Appears Designed to Enable Tiptree Management to Extract Value from Shareholders While Running a Blank Check Company Intends to Vote AGAINST the Unfair Transaction, Which Is Structured to Benefit Tiptree Management at the Expense of Tiptree Shareholders Urges the Tiptree Board of Directors to Restructure the Transaction and Deliver the $28.75 per Share Consideration Directly to Tiptree Shareholders,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved